debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC
August 2000
There's lots of debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC.
The FDA is holding meetings...and considering a switch.
The Amer Pharmaceutical Assoc strongly supports it.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote